ReviewImmunotherapy2009
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.
Review in Immunotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- Recent advances in regulatory immune cells: exploring the world beyond Tregs.Frontiers in immunology · 2025Review
- Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.Journal of translational medicine · 2022Article
- Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation.Oxidative medicine and cellular longevity · 2022Article
- Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.Journal of experimental & clinical cancer research : CR · 2020Review
- Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.The Journal of clinical investigation · 2020Article
- Dendritic Cells Treated with Exogenous Indoleamine 2,3-Dioxygenase Maintain an Immature Phenotype and Suppress Antigen-specific T cell Proliferation.Journal of immunology and regenerative medicine · 2019Article
- Allergen Delivery Inhibitors: A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens through Structure-Based Protease Inhibitor Design.Molecular pharmacology · 2018Review
- Article
- A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.Scientific reports · 2017Article
- Strategies for Increasing Pancreatic Tumor Immunogenicity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Identification and Evaluation of New Immunoregulatory Genes in Mesenchymal Stromal Cells of Different Origins: Comparison of Normal and Inflammatory Conditions.Medical science monitor basic research · 2017Article
- Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease.Frontiers in immunology · 2016Review
- Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.Disease markers · 2016Article
- Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015Review
- Alternative kynurenic acid synthesis routes studied in the rat cerebellum.Frontiers in cellular neuroscience · 2015Article
- STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?Expert review of clinical immunology · 2015Review
- New insights into the role of the aryl hydrocarbon receptor in the function of CD11c⁺ cells during respiratory viral infection.European journal of immunology · 2014Article
- Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in vivo.The Journal of investigative dermatology · 2014Article
- The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.Molecular biology reports · 2014Article
- Emerging immunotherapies for rheumatoid arthritis.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.